These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27321184)

  • 21. CRAF R391W is a melanoma driver oncogene.
    Atefi M; Titz B; Tsoi J; Avramis E; Le A; Ng C; Lomova A; Lassen A; Friedman M; Chmielowski B; Ribas A; Graeber TG
    Sci Rep; 2016 Jun; 6():27454. PubMed ID: 27273450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
    Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
    Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
    Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
    J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
    Fallahi-Sichani M; Becker V; Izar B; Baker GJ; Lin JR; Boswell SA; Shah P; Rotem A; Garraway LA; Sorger PK
    Mol Syst Biol; 2017 Jan; 13(1):905. PubMed ID: 28069687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
    Shen CH; Kim SH; Trousil S; Frederick DT; Piris A; Yuan P; Cai L; Gu L; Li M; Lee JH; Mitra D; Fisher DE; Sullivan RJ; Flaherty KT; Zheng B
    Nat Med; 2016 Sep; 22(9):1056-61. PubMed ID: 27500726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation.
    Roh MR; Kim JM; Lee SH; Jang HS; Park KH; Chung KY; Rha SY
    J Dermatol; 2015 Sep; 42(9):881-8. PubMed ID: 26047064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
    Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    Tate SC; Burke TF; Hartman D; Kulanthaivel P; Beckmann RP; Cronier DM
    Br J Cancer; 2016 Mar; 114(6):669-79. PubMed ID: 26978007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
    Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
    EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specifically targeting ERK1 or ERK2 kills melanoma cells.
    Qin J; Xin H; Nickoloff BJ
    J Transl Med; 2012 Jan; 10():15. PubMed ID: 22277029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
    Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
    Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vemurafenib induces senescence features in melanoma cells.
    Haferkamp S; Borst A; Adam C; Becker TM; Motschenbacher S; Windhövel S; Hufnagel AL; Houben R; Meierjohann S
    J Invest Dermatol; 2013 Jun; 133(6):1601-9. PubMed ID: 23321925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.